Teva VP Ika Abravanel resigns
Uzi Sofer told "Bloomberg": We are in discussions with several large companies interested in partnering with us.
Brainsway Ltd. (TASE:BRIN) expects to reach an agreement this quarter for a medical-device company to market its non-invasive system to treat depression in the US, CEO Uzi Sofer told "Bloomberg" in an interview.
Earlier this month, Brainsway obtained US Food and Drug Administration (FDA) approval to use the company's Deep TMS (transcranial magnetic stimulation) device for the treatment of depression in patients who fail to respond to medication during a depression episode.
Currently, these patients receive electroconvulsive therapy (ECT), despite the strong negative image of the therapy. One million ECT treatments are carried out in the US each year. Sofer says that Deep TMS is just as effective as ECT, but without the side effects. There has been no comparative clinical trial of the two therapies to date.
Sofer told "Bloomberg", "We are in discussions with several large companies interested in partnering with us. Our next step is to reach a deal with a distributor." He declined to disclose which companies Brainsway was in talks with, though he said they included some of the largest in the industry.
Sofer also told "Bloomberg", "We are looking to be in the Nasdaq because this is the right place to be,” said Sofer. “The reason is not so much to raise money as it is to give the company its real valuation."
"Bloomberg" notes that that a US listing may boost Brainsway’s value by exposing it to more investors and possibly attracting analyst coverage, and that no analysts follow the company. It adds that Brainsway's share price has soared 68% this year after winning US and Canadian regulatory approval, and that the company would join drug developer Kamada Ltd. (TASE: KMDA) and translation software developer Babylon Ltd. (TASE:BBYL) in seeking Nasdaq listings this year as trading in Tel Aviv dwindles.
Published by Globes [online], Israel business news - www.globes-online.com - on January 21, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.